Log in

Relevant bibliographies by topics / Wen jian / Journal articles

To see the other types of publications on this topic, follow the link: Wen jian.

Journal articles on the topic 'Wen jian'

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Wen jian.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Chao, Xue-lin, Shu-zhen Jiang, Jian-wen Xiong, Jin-qiong Zhan, Bo Wei, Chun-nuan Chen, and Yuan-jian Yang. "Erratum to: Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics." Current Medical Science 40, no. 5 (October 2020): 997. http://dx.doi.org/10.1007/s11596-020-2256-3.

Full text

Abstract:

The article “Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics”, written by Xue-lin CHAO, Shu-zhen JIANG, Jian-wen XIONG, Jin-qiong ZHAN, Bo WEI, Chun-nuan CHEN, Yuan-jian YANG was originally published electronically on the publisher’s internet portal on June 2020 without open access. With the author(s)’ decision to opt for Open Choice, the copyright of the article is changed to © The Author(s) 2020 and the article is forthwith distributed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

APA, Harvard, Vancouver, ISO, and other styles

2

Төрбат, Цагаан. "Ашина овгийн хатны эртний геном нь Хөх түрэгийн хаант улсыг Зүүн хойд Азийн гаралтай болохыг харуулжээ." Mongolian Journal of Anthropology, Archaeology and Ethnology 13, no. 1 (May 10, 2024): 141–45. http://dx.doi.org/10.22353/mjaae.20241301013.

Full text

Abstract:

Xiao‐Min Yang, Hai‐Liang Meng, Jian‐Lin Zhang, Yao Yu, Edward Allen, Zi‐Yang Xia, Kong‐Yang Zhu, Pan‐Xin Du, Xiao‐Ying Ren, Jian‐Xue Xiong, Xiao‐Yu Lu, Yi Ding, Sheng Han, Wei‐Peng Liu, Li Jin, Chuan‐Chao Wang, and Shao‐Qing Wen. Ancient genome of Empress Ashina reveals the Northeast Asian origin of Göktürk Khanate. – Journal of Systematic and Evolution. Institute of Botany, Chinese Academy of Sciences. 2023. Volume 00 (0) 1-9.

APA, Harvard, Vancouver, ISO, and other styles

3

Diyaljee, Vishnu. "Discussion of “New Model for Predicting Permanent Strain of Granular Materials in Embankment Subjected to Low Cyclic Loadings” by Wen-Bo Chen, Wei-Qiang Feng, Jian-Hua Yin, Jin-Miao Chen, Lalit Borana, and Ren-Peng Chen." Journal of Geotechnical and Geoenvironmental Engineering 147, no. 11 (November 2021): 07021026. http://dx.doi.org/10.1061/(asce)gt.1943-5606.0002656.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chen, Wen-Bo, Wei-Qiang Feng, Jian-Hua Yin, Jin-Miao Chen, Lalit Borana, and Ren-Peng Chen. "Closure to “New Model for Predicting Permanent Strain of Granular Materials in Embankment Subjected to Low Cyclic Loadings” by Wen-Bo Chen, Wei-Qiang Feng, Jian-Hua Yin, Jin-Miao Chen, Lalit Borana, and Ren-Peng Chen." Journal of Geotechnical and Geoenvironmental Engineering 147, no. 11 (November 2021): 07021027. http://dx.doi.org/10.1061/(asce)gt.1943-5606.0002657.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Huang, Yu-zhou, Ming-Yi Sang, Pei-Wen Xi, Ruo-Xi Xu, Meng-Yuan Cai, Zi-Wen Wang, Jian-Yi Zhao, Yi-Han Li, Ji-Fu Wei, and Qiang Ding. "Abstract 7220: Emerging combination strategy: FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer." Cancer Research 84, no. 6_Supplement (March 22, 2024): 7220. http://dx.doi.org/10.1158/1538-7445.am2024-7220.

Full text

Abstract:

Abstract While polyADP-ribose polymerase (PARP) inhibitors have made advancements in the treatment of breast cancer, challenges such as chemotherapy resistance and limited application persist. Fanconi AnemiaComplementation Group I (FANCI), a DNA repair protein associated with breast cancer development, represents a potential target for novel combination therapeutic strategies. However, the role of FANCI in breast cancer and its impact on the efficacy of PARP inhibitors require further investigation. In our study, we analyzed FANCI expression in breast cancer tissues and cell lines, and its correlation with clinical parameters and patient prognosis. Lentiviral vectors were utilized and functional assays were performed to evaluate the effects of FANCI modulation on breast cancer cell growth and migration. Co-immunoprecipitation assays and protein interaction analysis were conducted to identify the interaction between FANCI and PARP1 and determine the specific binding region. The functionality and nuclear distribution of PARP1 were assessed upon FANCI modulation. Finally, the sensitivity of breast cancer cells to the PARP inhibitor talazoparib upon FANCI knockdown was evaluated in vitro and in vivo. Our findings demonstrated that FANCI was overexpressed in breast cancer and associated with poor prognosis. FANCI significantly promoted breast cancer cell proliferation both in vitro and in vivo. We identified the interaction between FANCI and PARP1, specifically at the FANCI helical domain 2 binding site. FANCI knockdown led to reduced nuclear localization of PARP1 and decreased PARP1 activity. Importantly, combination treatment with FANCI knockdown and talazoparib significantly inhibited cancer growth in vitro and in vivo. Additionally, we found that the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib, which effectively suppresses FANCI protein expression, exhibited a robust synergistic effect with talazoparib both in vitro and in vivo. In conclusion, FANCI is a novel therapeutic target for breast cancer. Suppression of FANCI regulates PARP1 redistribution and activity, making breast cancer cells more responsive to PARP inhibitors. This combination therapeutic strategy shows potential in enhancing the effectiveness of PARP inhibitors for breast cancer treatment, regardless of BRCA mutations. Citation Format: Yu-zhou Huang, Ming-Yi Sang, Pei-Wen Xi, Ruo-Xi Xu, Meng-Yuan Cai, Zi-Wen Wang, Jian-Yi Zhao, Yi-Han Li, Ji-Fu Wei, Qiang Ding. Emerging combination strategy: FANCI suppression induces PARP1 redistribution to enhance efficacy of PARP inhibitors in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7220.

APA, Harvard, Vancouver, ISO, and other styles

6

Shi, Guoming, Xiaoyong Huang, Tianfu Wen, Tianqiang Song, Ming Kuang, Haibo Mou, Lequn Bao, et al. "Abstract CT153: Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma Including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study." Cancer Research 83, no. 8_Supplement (April 14, 2023): CT153. http://dx.doi.org/10.1158/1538-7445.am2023-ct153.

Full text

Abstract:

Abstract Background: Pemigatinib is a selective FGFR inhibitor that showed effectiveness and tolerability in patients with cholangiocarcinoma (CAA) with FGFR2 fusion or rearrangement. Data from prior data cutoffs (primary: Jan 29th, 2021; initial update: Dec 20th, 2021) showed that patients receiving pemigatinib had durable responses. Confirmed objective response rate (ORR) (60%) met the primary endpoint, median duration of response (DOR) was 8.3 months, median progression-free survival (PFS) was 9.1 months at the initial update (G-M. Shi et al. ASCO 2022). Safety results were also consistent with previously reported data on pemigatinib. Here we report updated overall survival (OS) results. Methods: Patients aged 18 years or older with recurrent or metastatic CCA that failed at least one prior systemic therapy were enrolled. Thirty-one subjects with documented FGFR2 fusion or rearrangement received 13.5 mg pemigatinib. The primary efficacy endpoint was ORR assessed by the independent radiological review committee (IRRC) per RECIST V1.1. And the second endpoints included disease control rate (DCR), DOR, PFS, and OS. Updated OS were evaluated by Cox proportional hazards model and summarized using Kaplan-Meier methods. Results: At data cutoff (December 28th, 2022), a total of 30 patients were assessed (1 participant excluded due to inadequate FGFR2 aberrant frequency). Median age was 56 years (range, 28-68).With a median OS follow-up of 25.6 months (95% CI, 23.0-25.8), the median OS was 23.9 months (95% CI, 15.2-NC), with 16 (53.3%) OS events. Estimated OS rate at 12 month, 18 month and 24 month were 73.3% (95% CI, 53.7%-85.7%), 66.5% (95% CI, 46.7%-80.4%), and 41.4% (95% CI, 22.4%-59.4%), respectively. No new safety signals were observed. Conclusions: These updated results demonstrated encouraging and durable survival benefit of pemigatinib in Chinese patients with recurrent or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement. Clinical trial identification: NCT04256980. Editorial acknowledgment: Guoming Shi and Xiaoyong Huang contributed equally to this work. Jian Zhou is the corresponding author. Citation Format: Guoming Shi, Xiaoyong Huang, Tianfu Wen, Tianqiang Song, Ming Kuang, Haibo Mou, Lequn Bao, Haitao Zhao, Hong Zhao, Xielin Feng, Bixiang Zhang, Tao Peng, Yubao Zhang, Xiangcheng Li, Hongsheng Yu, Yu Cao, Yang Luo, Ye Chen, Mingxia Chen, Jia Fan, Jian Zhou. Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma Including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT153.

APA, Harvard, Vancouver, ISO, and other styles

7

Lin, Ziyou, Jingwei Li, Jian Zhang, Weineng Feng, Jiaye Lu, Xiaofan Ma, Wen Ding, et al. "Abstract 415: Metabolic reprogramming driven by IGF2BP3-COX6B2 axis promotes acquired resistance to EGFR-TKIs in non-small lung cancer." Cancer Research 83, no. 7_Supplement (April 4, 2023): 415. http://dx.doi.org/10.1158/1538-7445.am2023-415.

Full text

Abstract:

Abstract Acquired resistance represents a bottleneck to molecular targeted therapy in lung cancer. Metabolic adaptation is a distinct hallmark of human lung cancer, but its role in acquired resistance has not been fully understood. In this study, we discovered a novel mechanism of TKI resistance involved in IGF2BP3-dependent crosstalk between the epigenetic modifications and metabolic reprogramming through the IGF2BP3-COX6B2 axis. We demonstrated the upregulated expression of RNA binding protein IGF2BP3 reduced the sensitivity of TKI treatment and exacerbated the development of drug resistance via promoting oxidative phosphorylation (OXPHOS). Analysis of patient samples revealed a positive correlation between IGF2BP3 and COX6B2 and poor prognosis in lung cancer patients. We further confirmed that COX6B2 is a key downstream target in IGF2BP3-mediated acquired TKI-resistance. Mechanistically, IGF2BP3 bound to the 3’-untranslated region of COX6B2 in an m6A-dependent manner to increase COX6B2 mRNA stability. Moreover, IGF2BP3 significantly enhanced OXPHOS capacity in lung cancer through the IGF2BP3-COX6B2 axis by regulating nicotinamide metabolism, thus resulting in TKI resistance in lung cancer. Inhibition of OXPHOS with IACS-010759, a small-molecule inhibitor, resulted in remarkable growth inhibition in vitro and in vivo in a gefitinib-resistant patient-derived xenograft model. Collectively, our findings suggest that metabolic reprogramming directed by the IGF2BP3-COX6B2 axis plays a critical role in TKI resistance, and targeting the metabolic pathway provides a new therapeutic strategy to overcome EGFR-TKI resistance in lung cancer. Citation Format: Ziyou Lin, Jingwei Li, Jian Zhang, Weineng Feng, Jiaye Lu, Xiaofan Ma, Wen Ding, Shumin Ouyang, Jinjian Lu, Peibin Yue, Guohui Wan, Peiqing Liu, Xiaolei Zhang. Metabolic reprogramming driven by IGF2BP3-COX6B2 axis promotes acquired resistance to EGFR-TKIs in non-small lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 415.

APA, Harvard, Vancouver, ISO, and other styles

8

Xue, Wei-Wei, Huan-Nan Wang, Zhi-Meng Wang, Meng-Xi Qiu, Jing Che, Feng-Jiao Deng, and Jiang-Dong Liu. "Cloning and Characterization of ifitm1 and ifitm3 Expression During Early Zebrafish Development - CORRIGENDUM." Zygote 24, no. 1 (July 21, 2015): 159. http://dx.doi.org/10.1017/s0967199415000398.

Full text

Abstract:

The authors apologise for errors in the corresponding authors details given on page 1 of the article. Below is the correct information of the corresponding author and email address :1) Wei-Wei Xue, Huan-Nan Wang, Zhi-Meng Wang, Meng-Xi Qiu, Jing Che, Feng-Jiao Deng* and Jiang-Dong Liu*2) *All correspondence to: Feng-Jiao Deng and Jiang-Dong Liu. e-mail: fish4@whu.edu.cn3) All authors are from the same one laboratory. The second laboratory was superfluous and should be deleted.

APA, Harvard, Vancouver, ISO, and other styles

9

Hsu, Yuan Hung, Chih-Lung Chen, Jhih-Yun Jian, Ming-Cheng Wei, Wen-Yuan Hsieh, Chia-Wen Huang, Yung-Chu Chen, Tzu-Hsin Liao, and Shian-Jy Wang. "Abstract 818: Preclinical studies of the cabazitaxel nanoformulation MPB-1734 support therapeutic application in chemo-resistant solid tumors and synergistic benefit in combination with immune checkpoint inhibitor." Cancer Research 83, no. 7_Supplement (April 4, 2023): 818. http://dx.doi.org/10.1158/1538-7445.am2023-818.

Full text

Abstract:

Abstract Background: Cabazitaxel (CBZ) is a second-generation taxane that has the potential to overcome taxane-resistance due to the low affinity for the P-glycoprotein efflux pump. However, with the high systemic toxicity such as neutropenia and hypersensitivity, the clinical use is restricted to patients with metastatic castration-resistant prostate cancer who show progression after docetaxel-based chemotherapy. MPB-1734 is a CBZ nanoformulation which is currently being evaluated as monotherapy in patients with advanced solid tumors in a Phase 1/2a trial (NCT04643418). It is developed to overcome the limitations associated with CBZ application and as potential therapeutic agent for chemo-resistant cancers. This work outlines the results of preclinical studies that support the tumor targeting ability, improved safety profiles, significant therapeutic effect, and synergistic benefit in combination with immune checkpoint inhibitor. Methodology: A series of nonclinical studies of MPB-1734 were conducted including toxicology evaluations in two species and the antitumor activity evaluations in a range of xenograft mice models as cervical cancer (KB), ovarian cancer (OVCAR3) and platinum-resistant human ovarian cancer patient-derived-xenograft (PDX) model (OV0276). The antitumor activity of MPB1734 combined with anti-PD-1 antibody were also evaluated in the syngenetic 4T1 breast cancer mice model. Results: Toxicology evaluations of MPB-1734 demonstrated the safety profiles of CBZ were significantly improved, and the tolerated doses of MPB-1734 are at least 2 folds higher than commercial formulation. An in-vivo tumor targeting study showed that MPB1734 mainly accumulated in the tumor sites, rather than in the vital organs. MPB1734 exhibited a better efficacy compared to commercial formulation in KB and OVCAR3 models. For platinum-resistant PDX model, MPB-1734 demonstrated significant anti-tumor efficacy (TGI:100%, p<0.001). For 4T1 mice model, MPB-1734 combined with anti-PD-1 antibody demonstrated synergistic benefit (TGI: 78.6%) compared to anti-PD-1 antibody monotherapy (TGI: 2.8%) and MPB-1734 monotherapy (TGI: 52.9%). This synergistic benefit may result from increased CD8+ T cells in tumor region after MPB-1734 treatment. Conclusion: MPB-1734 can reduce the major dose-limiting side effect (neutropenia) of CBZ and increase the tolerated dose. With tumor targeting ability, superior antitumor effects were demonstrated as compared with commercial formulation in a range of cancer models. MPB-1734 combined with anti-PD-1 antibody showed synergistic benefit in tumor inhibition. These preclinical results support the potential use of MPB-1734 as therapeutic agent for chemo-resistant cancer with monotherapy or combination therapy with immuno-oncology agents. Citation Format: Yuan Hung Hsu, Chih-Lung Chen, Jhih-Yun Jian, Ming-Cheng Wei, Wen-Yuan Hsieh, Chia-Wen Huang, Yung-Chu Chen, Tzu-Hsin Liao, Shian-Jy Wang. Preclinical studies of the cabazitaxel nanoformulation MPB-1734 support therapeutic application in chemo-resistant solid tumors and synergistic benefit in combination with immune checkpoint inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 818.

APA, Harvard, Vancouver, ISO, and other styles

10

Luo, J., Q. Y. Su, J. Q. Zhang, J. Qiao, S. X. Zhang, C. Wang, and X. F. LI. "POS1353 COMPOSITION AND ASSOCIATIONS OF THE GUT MICROBIOTA IN BECHET’S DISEASE WITH PERIPHERAL LYMPHOCYTE SUBSETS AND CYTOKINES." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 1015.2–1015. http://dx.doi.org/10.1136/annrheumdis-2022-eular.3430.

Full text

Abstract:

BackgroundBechet’s disease (BD) is a chronic multisystemic vasculitis with genetic and abnormal immune response. Growing evidences suggests gut microbiota compositional alteration may have an association with immune dysfunction in patients with BD.ObjectivesThis study aims to investigate the gut microbiota between BD and healthy controls (HCs) and analyse relevancy between bacterial and peripheral lymphocyte subsets and cytokines.MethodsFecal samples obtained from 22 BD patients and 22 normal-age and gender-matched HCs in this study. The gut microbiota were assessed with 16s rRNA sequencing and the flow cytometry was used to dectect peripheral lymphocyte subsets. C-reaction protein (CRP), Erythrocyte sedimentation rate (ESR), complement C3 and C4 were also assigned for disease activity measure. The edgeR package was used for differential abundance analysis. Difference of alpha diversity indices, bacterial abundances, and the F/B ratio were carried out using the Wilcoxon rank-sum test (R v.4.0.1). The differential abundance of flora and CRP, ESR, C3 and C4 between BD patients and HCs was assessed by pearson’s correlation analysis.ResultsAs for alpha diversity, the Shannon (p < 0.05) and Simpsonance analysis. Difference of alpha diversity indices, bacterial abundances, and the F/B ratio were carried out using the Wilcoxon rank-sum test (R v.4.0.1). The differential abundamicrobial community structures between BD and HCs (R = 0.053, p = 0.051; Figure 1B). The gut microbiota compositions of BD differed form those of HCs (Figure 1C). Four species of flora distinctly difference were found in BD (p < 0.05; Figure 1D). There was significant positive correlations between Tregs and Verrucomicrobiota (p < 0.05), and Proteobacteria (p < 0.05), Th1 and Proteobacteria (p < 0.05), ESR and Verrucomicrobiota (p < 0.01), but negatives correlation between TNF-α and Desulfobactbiota (p < 0.05; Figure 1E).ConclusionPattients with CTD had disbiosis of gut microbiota charaterized by impared diversity and abnomal composition, which was closely correlated with peripheral lymphocyte subsets and disease activity measures.References[1]Margaret Alexander, Qi Yan Ang, Renuka R Nayak, et al. Human gut bacterial metabolism drives Th17 activation and colitis. Cell Host Microbe. 2022 Jan 12;30(1):17-30.e9. doi: 10.1016/j.chom.2021.11.001. Epub 2021 Nov 24.[2]Yi-Wen Tsai, Jia-Ling Dong, Yun-Jie Jian, et al. Gut Microbiota-Modulated Metabolomic Profiling Shapes the Etiology and Pathogenesis of Autoimmune Diseases. Microorganisms. 2021 Sep 10;9(9):1930. doi: 10.3390/microorganisms9091930.AcknowledgementsThis work was supported by the National Natural Science Foundation of China (No. 82001740).Disclosure of InterestsNone declared

APA, Harvard, Vancouver, ISO, and other styles

11

Hermanson, Greg T. "Chromatography: Methods and Protocols. Volume 147, Methods in Molecular Biology Edited by Pascal Bailon, George K. Ehrlich, Wen-Jian Fung, and Wolfgang Berthold. Humana Press, Totowa, NJ. 2000. x + 230 pp. 15.5 × 23.5 cm. ISBN 0-89603-694-4. $79.50." Journal of Medicinal Chemistry 43, no. 22 (November 2000): 4332. http://dx.doi.org/10.1021/jm0003790.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Liu, Chan-Chuan, Chia-Hung Chien, Wen-Bin Yang, Jian-Ying Chuang, and Kwang-Yu Chang. "Abstract 5867: Multimodal analysis of glioblastoma identifies the additional function of CXCL12 for modulating GBM resistance and immunosuppressive microenvironment." Cancer Research 83, no. 7_Supplement (April 4, 2023): 5867. http://dx.doi.org/10.1158/1538-7445.am2023-5867.

Full text

Abstract:

Abstract Glioblastoma (GBM), a WHO Grade IV glioma, is the most common and aggressive primary brain tumor. Despite the standard of care consisting of surgery removal following radio- and chemo- therapy, the prognosis of GBM patients remain dismal. The interplay between GBM cells and its microenvironment contributes to maintaining the cancer stemness, developing resistance, and forming immunosuppression. GBM-associated macrophages (GAMs) are recruited to the GBM microenvironment by cytokines/chemokines. Conversely, GAMs may promote GBM progression. Therefore, we hypothesized that GBM cells modulated immune microenvironment via macrophage activation. We integrated the bulk RNA sequencing (seq.) of the paired primary-recurrent GBM specimens, single-cell RNA seq., and in vitro validation to investigate the hypothesis. The bulk RNA seq. of the paired primary-recurrent GBM specimens indicated that recurrent GBM enhanced the neuroinflammation pathway. Among the components, we found that CXCL12, also known as stromal cell-derived factor 1 was accumulated during GBM progression and up-regulated in temozolomide (TMZ)-resistant GBM cells. On the other hand, the newly CXCL12 receptor CXCR7 may act as a scavenger for CXCL12 during developing TMZ resistance in GBM. The bulk RNA sequencing seq. from primary-recurrent GBM specimens showed the decrement of CXCR7. Single-cell RNA seq. of GBM patients’ specimens indicated CXCR7 dominantly expressed in GBM cells other than normal neural and immune cells. Developing TMZ resistance in GBM cell lines down-regulated CXCR7 expression. Furthermore, silencing CXCR7 attenuated TMZ cytotoxicity while combining CXCR7 agonists (Plerixafor, VUF11207, and TC14012) and TMZ enhanced TMZ cytotoxicity. Otherwise, the GBM-associated CXCL12 activated M0 macrophages into GAMs by facilitating macrophage proliferation and inducing pro-tumor factors, including interleukine (IL)-1β and its receptors, IL-6, MMP9, and immune checkpoint PD-L1. Mechanistically, GBM-associated CXCL12 upregulated PD-L1 in GAMs via NF-κB. Accordingly, by multimodal analysis, CXCL12 was identified with the additional role in regulating resistance in GBM cells and GBM microenvironment. Also, re-activating CXCR7 may overcome the resistance to TMZ and immune checkpoint blockade therapy. Combination of CXCR7 activation with current therapy and immunotherapy may be an effective strategy for improving the prognosis of primary GBM patients. Citation Format: Chan-Chuan Liu, Chia-Hung Chien, Wen-Bin Yang, Jian-Ying Chuang, Kwang-Yu Chang. Multimodal analysis of glioblastoma identifies the additional function of CXCL12 for modulating GBM resistance and immunosuppressive microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5867.

APA, Harvard, Vancouver, ISO, and other styles

13

Diao, Wen-Hui. "An analysis of “insight” in Jiao Ran's Shishi -Also Jiao Ran’s view of Wei and Jin demeanour-." JOURNAL OF CHINESE HUMANITIES 70 (December 31, 2018): 57–65. http://dx.doi.org/10.35955/jch.2018.12.70.57.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

DENG, WEI-AN, LEI XIN, RONG-JIAO ZHANG, CHAO-MEI HUANG, HAI-QING XU, LIU-SU TAN, and SU-QIN HUANG. "New species and new synonyms of Macromotettixoides (Orthoptera: Tetrigidae) with an updated key." Zootaxa 4852, no. 1 (September 14, 2020): 41–60. http://dx.doi.org/10.11646/zootaxa.4852.1.2.

Full text

Abstract:

The genus Macromotettixoides Zheng, Wei & Jiang, 2005 is reviewed. Four new species of the genus, M. daiyunshanensis Deng, sp. nov., M. curvicarina Deng, sp. nov., M. convexa Deng, sp. nov. and M. shengtangshanensis Deng, sp. nov. are described with detailed illustrations of external morphology. Two new synonyms are established: M. jinggangshanensis, syn. nov. is synonymized with M. jiuwanshanensis Zheng, Wei & Jiang, 2005; M. parvula Zha & Wen, 2017, syn. nov. is synonymized with M. undulatifemura Deng, Zheng & Yang, 2012. Additionally, an updated key to species of the genus is given.

APA, Harvard, Vancouver, ISO, and other styles

15

Zhang, Lei, Ao Li, Shanzhong Jian, Chengyi Du, Wan Zhu, Yue Tao, Meiwei Wang, et al. "Abstract 429: Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer." Cancer Research 83, no. 7_Supplement (April 4, 2023): 429. http://dx.doi.org/10.1158/1538-7445.am2023-429.

Full text

Abstract:

Abstract KRAS is the predominantly mutated RAS isoform, accounting for 85% of RAS mutations in cancers. KRAS G12C mutation occurs in approximately 14% of lung adenocarcinomas and 3% of colorectal adenocarcinomas. Several drugs have been developed that inhibit the function of KRAS proteins with a “G12C” mutation. The response rate to these drugs in patients with KRAS G12C-mutated NSCLC is approximately 40%. Primary resistance to G12C inhibitors in these patients may be explained in part by a lack of dependency on KRAS signaling. Despite the clinical benefit observed in some patients treated with G12C inhibitors, acquired resistance to single-agent inhibitor therapy eventually develops in most patients. KRAS G12C-mutated NSCLC cell lines treated with G12C- specific inhibitor demonstrated reactivation of the down-stream MAPK pathway as a mechanism of acquired resistance. As a terminal kinase in this pathway, inhibition of ERK1/2 activity could potentially be instrumental in overcoming G12C inhibitor resistance. Moreover, aurora kinase A (AURKA) has been identified as necessary for cancer cell escape from G12C inhibitor-induced quiescence, which may be due to a stabilizing reaction between AURKA, KRAS G12C and the downstream effector CRAF. JSI-1187 is an oral reversible ERK1/2 inhibitor, and VIC-1911 is an oral selective AURKA inhibitor. To evaluate the effects of the concomitant inhibition of JSI-1187 or VIC-1911 with sotorasib, we assessed the response in 4 G12C-mutated cell lines, including two NSCLC and two CRC. Loewe synergy scores calculated showed values between 0.5 to 14.3 in these cell lines, which signified a synergistic effect of JSI-1187 or VIC-1911 combined with sotorasib. JSI-1187 or VIC-1911 combined with sotorasib or adagrasib demonstrated marked enhancement of the antitumor effect compared with single-agent treatment in a H2122 mouse xenograft model. Additionally, the antitumor growth effect of JSI-1187 and sotorasib was significantly better than the combination of the MEK inhibitor, trametinib, and sotorasib. Greater inhibition of tumor growth was also observed for the combination vs. monotherapy in H358 and SW837 CRC- bearing mouse models. Furthermore, KRAS G12C-mutated patient-derived xenografts were used to investigate a synergistic effect. Combined treatment with VIC-1911 and sotorasib demonstrated greater tumor growth inhibition than either monotherapy alone in a NSCLC PDX model. In addition, the combination of JSI-1187 and sotorasib demonstrated a significant increase in tumor growth inhibition in a CRC PDX model. Taken together, our preclinical studies suggest that the combination of an ERK inhibitor, JSI-1187, or an AURKA inhibitor, VIC-1911, may potentially overcome the primary resistance and prevent or delay the acquired resistance to G12C inhibitors. Citation Format: Lei Zhang, Ao Li, Shanzhong Jian, Chengyi Du, Wan Zhu, Yue Tao, Meiwei Wang, Wen Xu, Wenshan Hao, Linda Paradiso, Thomas Myers, Keizo Koya, Jintao Zhang. Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 429.

APA, Harvard, Vancouver, ISO, and other styles

16

Wu, Jiong, Jian Zhang, Yiqun Du, Wen Zou, Muran Ding, Hui Yang, Sa Xiao, et al. "Abstract PS08-07: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study." Cancer Research 84, no. 9_Supplement (May 2, 2024): PS08–07—PS08–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-ps08-07.

Full text

Abstract:

Abstract Background: BL-B01D1 is a first-in-class novel antibody drug conjugate (ADC) consisting of an EGFRxHER3 bispecific antibody bounded to a novel TOP-I inhibitor payload via a cleavable linker. We now present safety/efficacy data from a phase I study of BL-B01D1 in breast cancer. Methods: This study included patients (pts) with locally advanced or metastatic breast cancer (BC) and other solid tumors. BL-B01D1 was administered intravenously at doses of 2.5mg/kg Day 1 & Day 8 every 3 weeks (D1D8Q3W) or 5.0mg/kg Day 1 every 3 weeks (D1Q3W) during dose escalation (D-ESC, i3+3) based on the information obtained during the first-in-human study in solid tumors. A subset of pts will be enrolled in the dose-expansion (D-EXP) phase. Results: As of June 26, 2023, 42 pts were enrolled and received at least one dose (D-ESC, n=8; D-EXP, n=34) of BL-B01D1. Only one DLT of febrile neutropenia was observed at 5.0mg/kg D1 Q3W, maximum tolerated dose (MTD) has not been reached. D-EXP was conducted at 2.5mg/kg D1D8 Q3W. Forty-one pts with BC and 1 pt with non-small cell lung cancer (NSCLC) were enrolled in this study. The most common TRAEs ( >10%, all grade/≥ G3) were leukopenia (67%/24%), neutropenia (55%/33%), anemia (55%/26%), thrombocytopenia (60%/24%), nausea (38%/0%), vomiting (38%/0%), stomatitis (31%/2%), asthenia (29%/0%), hypokalemia (21%/5%), aspartate aminotransferase increased (19%/0), alanine aminotransferase increased (19%/0%), decreased appetite (19%/0%), hypertriglyceridemia (19%/0%), hyperglycemia (19%/0%), hyperglycemia (17%/0%), weight decreased (14%/0%), diarrhea (12%/0%), epistaxis (12%/0%), hypercholesterolemia (12%/0%). No ILD was observed. Twenty-four pts. were evaluable for efficacy (at least 1 tumor assessment). Updated information will be provided during the meeting. Conclusions: BL-B01D1 demonstrated encouraging efficacy in metastatic/locally advanced breast cancer that have failed standard of care, especially in pts with TNBC. The safety profile showed adequate safety and tolerability. Clinical trial information: NCT05470348. Efficacy in Patients with Breast Cancer 1 Including pts whose PRs were not yet confirmed but still under treatment. Citation Format: Jiong Wu, Jian Zhang, Yiqun Du, Wen Zou, Muran Ding, Hui Yang, Sa Xiao, Hongwei Wang, Hai Zhu, Martin Olivo, Yi Zhu. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PS08-07.

APA, Harvard, Vancouver, ISO, and other styles

17

Xiao, Yuting, Yuqiu Ke, and Yijian Sun. "Influence Of Spot Size On LA-ICP-MS Ablation Behavior For Synthetic Calcium Tungstate And Silicate Glass Reference Material NIST SRM 610." Atomic Spectroscopy 42, no. 1 (January 1, 2021): 36–42. http://dx.doi.org/10.46770/as.2021.01.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

DENG, WEI-AN. "Taxonomic revision of the subfamily Cladonotinae (Orthoptera: Tetrigidae) from China with description of three new species." Zootaxa 4789, no. 2 (June 9, 2020): 403–40. http://dx.doi.org/10.11646/zootaxa.4789.2.5.

Full text

Abstract:

The Chinese genera and species of the subfamily Cladonotinae are reviewed. A checklist is given for all genera and species. Three new species are described from China: Pseudepitettix hainanensis sp. nov. (Hainan prov.), Pseudepitettix strictivertex sp. nov. (Hainan prov.) and Tuberfemurus convexa sp. nov. (Zhejiang prov.). New synonymies are proposed: Deltonotus hainanensis Zheng & Liang, 1985 = Deltonotus wuzhishanensis Lin & Zheng, 2014, syn. nov., Gibbotettix emeiensis Zheng, 1992 = Gibbotettix serrifemura Deng, Zheng & Wei, 2016, syn. nov., Gibbotettix emeiensis Zheng, 1992 = Gibbotettix longivalva Zha & Li, 2018, syn. nov., Pseudepitettix nigritibis Zheng & Jiang, 2000 = Tuberfemurus liboensis Deng, Zheng & Wei, 2009, syn. nov., Yunnantettix bannaensis Zheng, 1995 = Yunnantettix variabilis Zha & Wen, 2016, syn. nov., Yunnantettix thaicus Storozhenko & Pushkar, 2015 = Yunnantettix nanensis Zha & Wen, 2015, syn. nov. Four new combinations are established: Epitettix guangxiensis (Zheng & Jiang, 1994), comb. nov., Epitettix yunnanensis (Zheng, 1995), comb. nov., Gibbotettix undatimarginis (Deng & Zheng, 2012), comb. nov., Pseudepitettix torulosinota (Zheng & Lin, 2016), comb. nov.

APA, Harvard, Vancouver, ISO, and other styles

19

Ryujin, Nicolas T., Jian Huang, Albert Nguyen, Jared Edwards, Yuhe Cheng, Jessica Wen, Ashish Damania, et al. "Abstract 3974: Macronutrient composition dictates MASH-associated HCC immunosurveillance through microbiota alteration and metabolic adaptation." Cancer Research 84, no. 6_Supplement (March 22, 2024): 3974. http://dx.doi.org/10.1158/1538-7445.am2024-3974.

Full text

Abstract:

Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with an estimated incidence of over one million cases by 2025. The advances in vaccines against HBV and HCV have led to a decrease in the number of virus-related cases; however, the obesity epidemic has contributed to a drastic increase in metabolic dysfunction-associated steatohepatitis (MASH) related HCC cases (e.g., obesity and type 2 diabetes induced HCC). Considering this trend, we aim to understand how lifestyle choices, like food composition, in combination with alcohol consumption at a “social drinking level” impacts host metabolism, and subsequently the development of MASH-induced HCC. We hypothesize that the impact of dietary composition on dysbiosis and immune cells, particularly adaptive immune cell metabolic status, will drive the phenotype. We have developed a MASH-induced HCC murine model, with long-term dietary intervention including seven different customized diets: normal chow (NC), ketogenic, solid high fat diet (sHFD), or isocaloric liquid Lieber DeCarli Diets (LDC): high fat/low carb (HF), high fat/low carb with ethanol (HF-EtOH), low fat/high carb (LF), and low fat/high carb with ethanol (LF-EtOH). Mice began special diet in late adolescences and disease progression was monitored over the course of a year, where mice developed HCC. Our model allowed for a comprehensive understanding of MASH-induced HCC where disease initiation could be studied beyond known contributors like obesity or body mass index (BMI). The animal model was analyzed comprehensively with high-parameter flow cytometry (FC), 16S sequencing, bulk RNA-seq, scRNA/ATAC-seq, and WGS. Long-term diet intervention led to macronutrient specific microbiota dysregulation, alterations in systemic metabolism and suppression of adaptive immune response, consequently impacting the progression of HCC. Customized dietary interventions showed a specific phenotype regarding HCC development and progression with distinct mutational genotype and particular response to immunotherapy. T and B cell subpopulation deficiency had a significant impact on MASH-induced HCC development in a macronutrient composition dependent manner. In summary, each dietary intervention showed a distinct pattern and effect on dysbiosis, systemic metabolic reprograming, cellular transcriptomic and epigenetic alteration, and particularly immune cell effector function. Additionally, some compositions supported the immuno-escape mechanism of malignant cells through regulation of their MHC machinery. Collectively, these accumulated data construct an atlas for understanding the underlying molecular mechanisms contributing to lifestyle-induced HCC providing the knowledge needed to advance effective strategies for treatment and prevention. Citation Format: Nicolas T. Ryujin, Jian Huang, Albert Nguyen, Jared Edwards, Yuhe Cheng, Jessica Wen, Ashish Damania, Nadim Ajami, Spencer Rosario, Mark Long, Ludmil Alexandrov, Shabnam Shalapour. Macronutrient composition dictates MASH-associated HCC immunosurveillance through microbiota alteration and metabolic adaptation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3974.

APA, Harvard, Vancouver, ISO, and other styles

20

Ball, Philip. "Jian-Wei Pan: building the quantum internet." National Science Review 6, no. 2 (September 21, 2018): 374–76. http://dx.doi.org/10.1093/nsr/nwy102.

Full text

Abstract:

Abstract For many decades since its inception in the early twentieth century, quantum mechanics seemed to be an exotic and peculiarly non-intuitive kind of physics that applied to matter at the smallest scales: the laws that govern atoms, photons and subatomic particles. All our engineering, meanwhile, was dominated by the familiar rules of classical physics, in which objects have definite positions, trajectories and properties. But, in the past several decades, scientists have started to harness quantum rules in practical technologies. In 1985, the physicist Richard Feynman suggested that computers governed by quantum rules might be capable of computations beyond the means of classical ones like those in use today. At much the same time, other researchers showed that information encoded in quantum states could be transmitted between a sender and receiver using a kind of encryption that could not be intercepted and read without that being detected. Quantum computers and quantum cryptography have now become central components of a real-world quantum-information technology that may soon find scientific, industrial and social uses. These applications could be increasingly enabled by a global information network with quantum capability: a quantum internet. China is at the forefront of that enterprise, and one of the scientific leaders in this effort is Jian-Wei Pan of the University of Science and Technology of China in Hefei. Pan studied for his PhD with quantum-information pioneer Anton Zeilinger in Vienna before returning to China to implement these nascent technologies. In 2012, he won the International Quantum Communication Award and, in 2017, he was included in Nature’s annual list of the ‘ten people who mattered in science’ over the past year. That July, he and his colleagues reported ‘quantum teleportation’ of photons from a ground-based station to a satellite 1400 km away. NSR recently interviewed Professor Pan about the current achievements and future prospects for quantum-information technologies.

APA, Harvard, Vancouver, ISO, and other styles

21

DongMinKim. "The Jin wen / Gu Wen Dedates(今古文論爭) and Jia Kui(賈逵)'s Zuo Zhuan Theory(左氏學)." Journal of Eastern Philosophy ll, no. 51 (August 2007): 183–224. http://dx.doi.org/10.17299/tsep..51.200708.183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Fang, Li-Zhi. "Jiang Xiaoyuan ;, Wu Yan . Zijin shan tian wen tai shi gao: Zhongguo tian wen xue xian dai hua ge an. [History of Purplemountain Observatory.] (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 219 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2004. 29 (paper)." Isis 99, no. 3 (September 2008): 645–46. http://dx.doi.org/10.1086/593267.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lu, Shun, Yongfeng Yu, Jianya Zhou, Koichi Goto, Xingya Li, Jun Sakakibara-Konishi, Kazumi Nishino, et al. "Abstract CT034: Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study)." Cancer Research 82, no. 12_Supplement (June 15, 2022): CT034. http://dx.doi.org/10.1158/1538-7445.am2022-ct034.

Full text

Abstract:

Abstract Background: METex14 mutations was reported in 3~4% of NSCLC patients and became a new target in the treatment of NSCLC. SCC244 is a highly selective and potent oral MET inhibitor. This is the first report of data from an ongoing single-arm phase II study of SCC244 in NSCLC patients with METex14 mutations (GLORY study). Methods: GLORY study is an open label, international, multi-center, single-arm phase II study to evaluate the efficacy and safety of SCC244 in patients with locally advanced or metastatic NSCLC harboring METex14 mutations which was confirmed by central laboratory. The enrolled patients have either failed one or two prior lines of systemic therapies or been not eligible/refused chemotherapy after being well-informed. SCC244 was taken orally at a dose of 300 mg once daily in 21-day treatment cycles until disease progression or intolerable toxicity. Tumor was evaluated every 6 weeks for the first 8 treatment cycles and every 9 weeks thereafter. The primary endpoint was objective response rate (ORR) assessed by blinded independent review committee (BIRC) per RECIST 1.1, secondary endpoints include ORR by investigator assessment (INV), duration of response (DoR), time to response (TTR) and safety etc. Post-hoc analysis was done to explore the intracranial anti-tumor activity. Results: At data cut-off on May 6th, 2021, a total 73 patients screened from 163 patients in 42 sites were treated at 300 mg QD dose and had ≥2 post-baseline tumor assessments or discontinued for any reason. 69 of them were with METex14 mutation confirmed by central laboratory. In the 69 patients, ORR by BIRC was 60.9% (95% CI: 48.4%, 72.4%) overall, 66.7% (95% CI: 50.5, 80.4) and 51.9% (95% CI: 31.9, 71.3) in treatment naïve and previously treated patients respectively. Median DoR was 8.2 months (95% CI: 4.8, NE) and median PFS was 7.6 months (95% CI: 4.2, NE), tumor response from 30 of 42 responders was still ongoing. The response occurred fast with a median TTR of 1.4 months (range: 1.2, 4.2). Partial response was observed in 8 of 10 patients with brain metastasis. 5 patients who had brain metastasis selected as targeted lesion had intracranial response by INV with a median intracranial tumor shrinkage of 57% (range: 34%, 71%). The most common (≥20%) treatment-related adverse events (TRAEs) of any grade were peripheral edema, headache, nausea, loss of appetite, hypoalbuminemia, ALT increase and vomiting. The incidence of ≥ grade 3 TRAEs was 43.8%. TRAEs leading to treatment discontinuation occurred in 6.8% patients, among which peripheral edema was the most common (4.1%). Conclusions: The data shows high and robust efficacy of SCC244 in NSCLC patients with METex14 mutations across treatment lines and encouraging intracranial anti-tumor activity. The safety profile was favorable with manageable toxicity. The data supports SCC244 as a valuable targeted treatment option for METex14 NSCLC patients. Citation Format: Shun Lu, Yongfeng Yu, Jianya Zhou, Koichi Goto, Xingya Li, Jun Sakakibara-Konishi, Kazumi Nishino, Tanaka Kentaro, Lin Wu, Xuhong Min, Wei Zhang, Dingzhi Huang, Yongqian Shu, Chengzhi Zhou, Min Li, Xiaorong Dong, Chong Bai, Lu Li, Jiuwei Cui, Li Zhang, Lejie Cao, Xiaoling Li, AiMin Zang, Haruki Kobayashi, Yiping Zhang, Yan Yu, Xiuwen Wang, Terufumi Kato, Shoichiro Yamamoto, Yuki Shinno, Xiaoyan Lin, Yanqiu Zhao, Yanping Hu, Qitao Yu, Ziping Wang, Masahiro Kodani, Jian Fang, Jialei Wang, Meiqi Shi, Diansheng Zhong, Wen Dong, Hiroshi Tanaka, Yasuto Yoneshima, Minghui Sun, Jun Zhou, Qiuxia Wu, Meng Li. Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT034.

APA, Harvard, Vancouver, ISO, and other styles

24

Lee, Y. H. "Comment on "A Vertical Exposure of the 1999 Surface Rupture of the Chelungpu Fault at Wufeng, Western Taiwan: Structural and Paleoseismic Implications for an Active Thrust Fault," by Jian-Cheng Lee, Yue-Gau Chen, Kerry Sieh, Karl Mueller, Wen-Shan Chen, Hao-Tsu Chu, Yu-Chang Chan, Charles Rubin, and Robert Yeats." Bulletin of the Seismological Society of America 93, no. 2 (April 1, 2003): 963–68. http://dx.doi.org/10.1785/0120020034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Li, Feng, and Peng-Yung Woo. "Computer recognition of Jia Gu Wen characters." International Journal of Imaging Systems and Technology 10, no. 4 (1999): 363–67. http://dx.doi.org/10.1002/(sici)1098-1098(1999)10:4<363::aid-ima8>3.0.co;2-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Volchkova, Elizaveta. "Death Beyond Death: Jian Spirits in Chinese Popular Belief." Journal of Ethnology and Folkloristics 17, no. 1 (June 1, 2023): 68–82. http://dx.doi.org/10.2478/jef-2023-0006.

Full text

Abstract:

Abstract This article* examines the origins and development of notions about jian spirits, beings into which, according to Chinese folk tradition, the souls of the dead transform after their demise. An analysis of the few available references to jian in Chinese literature and folklore suggests that the first mention of jian as ‘ghosts of ghosts’ appears relatively late, in the 13th century, as the result of a combination of two independent traditions: the written jian formula used in apotropaic practices from at least the Tang period (618–907), and a complex of ideas about the mortality of ghosts and their posthumous fate that took shape in the early Middle Ages, possibly under the influence of Buddhism. A detailed development of the ghosts of ghosts motif occurs as part of High Qing supernatural discourse in the works of writers Pu Songling and Yuan Mei. By the end of the 19th century notions that had been created by such literary representation were inherited by the popular belief system. The evolution of ideas about jian, which continues to the present, as far as one can judge from the supply on the market of magical paraphernalia and the material of modern supernatural web novels, provides a vivid example of how new concepts of Chinese folk religious tradition emerge and transform.

APA, Harvard, Vancouver, ISO, and other styles

27

Lima, Jane Glayce Pereira, Lais Alburquerque van der Linden, Renan Felipe Silva Santos, Rhaysa Allayde Silva Oliveira, Fabiano Sellos Costa, Jacinta Leite Brito, Helvio Rodrigues de Lima, and Evilda Rodrigues Lima. "Avaliação neuromotora de cães com afecções da coluna vertebral submetidos ao tratamento com acupuntura e moxabustão." Medicina Veterinária (UFRPE) 17, no. 2 (July 14, 2023): 95–102. http://dx.doi.org/10.26605/medvet-v17n2-5089.

Full text

Abstract:

Objetivando-se avaliar os aspectos neurológicos de cães com afecções na coluna vertebral, este estudo utilizou 14 animais adultos, de diferentes raças e ambos os sexos. Após os diagnósticos através de uma minuciosa avaliação clínica e da realização de exame radiográfico e tomografia computadorizada, foram submetidos ao tratamento da acupuntura e da moxabustão durante 120 dias, uma vez por semana, por 30 minutos, totalizando 20 sessões. Os pontos trabalhados foram: B23, B40, B60, VB20, VB30, VB34, VG1, VG2, VG 20, E36, R3, IG4; e os pontos extras foram: Jiang Jia ji, Hua Tuo Jia Ji e Wei Jian. Na primeira avaliação foi observada dor à palpação da coluna vertebral em todos os animais, sendo alguns com hirperestesia. Após a segunda sessão, os animais não manifestaram reação à dor. Dos 14 animais submetidos ao tratamento com acupuntura associada à moxabustão, 11 apresentaram progressão funcional total, com demonstração do retorno da marcha sem quedas e sem auxílio; dois apresentaram progressão parcial, quando retornaram a caminhar sem auxílio, porém com ataxia e quedas esporádicas; um com progressão funcional insatisfatória, com sinais neurológicos iniciais inalterados. A associação da técnica agulhamento e moxabustão foi eficaz para os quadros de dor e na reabilitação motora de cães com diferentes afecções neurológicas.

APA, Harvard, Vancouver, ISO, and other styles

28

Begikhani, Nazand, Wendelmoet Hamelink, and Nerina Weiss. "Theorising women and war in Kurdistan: A feminist and critical perspective." Kurdish Studies 6, no. 1 (May 27, 2018): 5–30. http://dx.doi.org/10.33182/ks.v6i1.432.

Full text

Abstract:

In this introductory article to the special issue Women and War in Kurdistan, we connect our topic to feminist theory, to anthropological theory on war and conflict and their long-term consequences, and to theory on gender, nation and (visual) representation. We investigate Kurdish women’s victimisation and marginalisation, but also their resistance and agency as female combatants and women activists, their portrayal by media and scholars, and their self-representation. We offer herewith a critical perspective on militarisation, women’s liberation, and women’s experiences in times of war and peace. We also introduce the five articles in this issue and discuss how they contribute to the study of women and war in two main areas: the wide-reaching effects of war on women’s lives, and the gendered representation and images of war in Kurdistan. ABSTRACT IN KURMANJIBîrdoza jin û şer li Kurdistanê. Perspektîveke femînîst û rexnegirîDi vê nivîsara danasîner a hejmara taybet a li ser Jin û Şer li Kurdistanê de, em mijarê behsê bi bîrdoza femînîst, bîrdoza mirovnasiyê ya şer û pevçûnan û encamên wan yên demdirêj, û bîrdoza zayend, netewe û nîşane (ya ditinî) ve girêdidin. Em li ser vederkirin û mexdûrkirina jinên kurd lêkolînê dikin, her wekî meseleya berxwedan û îradeya şervanên jin û çalakvanên mafên jinan, û pirsên ku çawa medya û lêkolîner qala wan dikin û çawa ew jî xwe didin nîşan. Em her weha perspektîveke li ser leşkerîkirin, azadkirina jinan û tecrubeyên jinan di heyamên şer û aştiyê de pêşberî xwendevanan dikin. Di ber re, em danasîna her pênc nivîsarên vê hejmarê jî dikin û girîngiya wan a ji bo lêkolînên jin û şerî di du warên sereke de guftûgo dikin: encamên berfireh yên şer li ser jiyana jinan, û nîşane û dimenên zayendî yên şer li Kurdistanê. ABSTRACT IN SORANIBe Tiyorîkirdinî rewşî jinan û ceng le Kurdistan: Goşenîgayekî fêmînîstî w rexnegiraneLem çend wutare da, ke melefêkî taybete be jinan û ceng le Kurdistan, hewlman dawe ke kogîrîyek bikeyn le ruwangey fêmînîstî w tiyorîy antropolojî leser ceng û milmilanê w akame dirêjxayenekanyan le layek û herweha tiyorîy regez, netewe w têruwanînî nwênerêtîkirdin le layekî dîke. Ême xwêndineweman kirdûwe bo kêşey bequrbanîbûn û perawêzxistinî jinan. Le heman kat da mijarî berxodan û xorêxistinî jinan wek cengawer û çalakanî mafî jinan û wêney ewan le rageyandin û lenêw lêkolînewe zanistiyekan û têruwanînî xoşyan da. Ême herweha têruwanînî rexnegiraneman leser mijarî çekdarî, azadîy jinan û ezmûnî jinan le katî ceng û aştî da xistote rû. Lem melefe taybete da, pênc wutarman pêşkêş kirdûwe w eweman nîşan dawe keçon le dû layenî giringewe tîşk xirawete ser mijareke: karîgerîy firawanî ceng le ser jiyanî jinan, herweha nuwandin û wêney regezî jinan le ceng le Kurdistan da.

APA, Harvard, Vancouver, ISO, and other styles

29

N., W. H., and Xu Gongchi. "Wei Jin wenxue shi." Chinese Literature: Essays, Articles, Reviews (CLEAR) 23 (December 2001): 181. http://dx.doi.org/10.2307/495518.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Yao, Wei. "An Analysis of the Changes on Life Consciousness of Literati from Jian'an to Zhengshi." International Journal of Education and Humanities 6, no. 3 (December 30, 2022): 5–8. http://dx.doi.org/10.54097/ijeh.v6i3.3917.

Full text

Abstract:

Wei and Jin Dynasties is a very special period in Chinese history. From Jian 'an to Zhengshi, it is a critical period of new changes and transition. The literary creation of this period and the life consciousness contained therein are worth further discussion. The most prominent expression in the literary theme is that people turn their attention from the realization of external individual value to the reflection on the intrinsic value of life, which is directly reflected in the discussion on the subject of life and death, that is, how to face death and how to live triggered by death. From Jian 'an to Zhengshi, this thought of life has a certain connection and development.

APA, Harvard, Vancouver, ISO, and other styles

31

Weng, Jian. "Editorial [Hot Topic: Nano-Organic Chemistry (Guest Editor: Dr. Jian Weng)]." Current Organic Chemistry 15, no. 21 (November 1, 2011): 3652. http://dx.doi.org/10.2174/138527211797884575.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

N., W. H., and Kakehi Fumio (Jian wen Sheng). "To So hakka bun (Tang song ba jia wen)." Chinese Literature: Essays, Articles, Reviews (CLEAR) 11 (December 1989): 171. http://dx.doi.org/10.2307/495542.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Lee, J. C. "Reply to "Comment on `A Vertical Exposure of the 1999 Surface Rupture of the Chelungpu Fault at Wufeng, Western Taiwan: Structural and Paleoseismic Implications for an Active Thrust Fault,' by Jian-Cheng Lee, Yue-Gau Chen, Kerry Sieh, Karl Mueller, Wen-Shan Chen, Hao-Tsu Chu, Yu-Chang Chan, Charles Rubin, and Robert Yeats," by Yuan-Hsi Lee, Shih-Ting Lu, Tung-Sheng Shih, and Wei-Yu Wu." Bulletin of the Seismological Society of America 93, no. 2 (April 1, 2003): 969–72. http://dx.doi.org/10.1785/0120020104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Yan, Jing, Yan Tang, Wei Yu, Lu Jiang, Chen Liu, Qi Li, Zhiqiang Zhang, et al. "Validation of the Anticolitis Efficacy of the Jian-Wei-Yu-Yang Formula." Evidence-Based Complementary and Alternative Medicine 2022 (August 31, 2022): 1–20. http://dx.doi.org/10.1155/2022/9110704.

Full text

Abstract:

Background. Inflammatory bowel disease (IBD) is a major cause of morbidity and mortality due to its repetitive remission and relapse. The Jian-Wei-Yu-Yang (JW) formula has a historical application in the clinic to combat gastrointestinal disorders. The investigation aimed to explore the molecular and cellular mechanisms of JW. Methods. 2% dextran sodium sulfate (DSS) was diluted in drinking water and given to mice for 5 days to establish murine models of experimental colitis, and different doses of JW solution were administered for 14 days. Network pharmacology analysis and weighted gene co-expression network analysis (WGCNA) were utilized to predict the therapeutic role of JW against experimental colitis and colitis-associated colorectal cancer (CAC). 16S rRNA sequencing and untargeted metabolomics were conducted using murine feces. Western blotting, immunocytochemistry, and wound healing experiments were performed to confirm the molecular mechanisms. Results. (1) Liquid chromatography with mass spectrometry was utilized to confirm the validity of the JW formula. The high dose of JW treatment markedly attenuated DSS-induced experimental colitis progression, and the targets were enriched in inflammation, infection, and tumorigenesis. (2) The JW targets were related to the survival probability in patients with colorectal cancer, underlying a potential therapeutic value in CRC intervention. (3) Moreover, the JW therapy successfully rescued the decreased richness and diversity of microbiota, suppressed the potentially pathogenic phenotype of the gut microorganisms, and increased cytochrome P450 activity in murine colitis models. (4) Our in vitro experiments confirmed that the JW treatment suppressed caspase3-dependent pyroptosis, hypoxia-inducible factor 1α (HIF1α), and interleukin-1b (IL-1b) in the colon; facilitated the alternative activation of macrophages (Mφs); and inhibited tumor necrosis factor-α (TNFα)-induced reactive oxygen species (ROS) level in intestinal organoids (IOs). Conclusion. The JW capsule attenuated the progression of murine colitis by a prompt resolution of inflammation and bloody stool and by re-establishing a microbiome profile that favors re-epithelization and prevents carcinogenesis.

APA, Harvard, Vancouver, ISO, and other styles

35

Hou, GuanQun, and MingYuan Lu. "Discussion on ＂Wei Qi Chu Shang Jiao＂." History and Philosophy of Medicine 2, no. 1 (2020): 14–20. http://dx.doi.org/10.53388/tmr2020d0101.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Shen, Grace Y. "Xuetong Li. Weng Wenhao nian pu [The Chronicle of Dr. Weng Wenhao]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 430 pp., bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. π¯16 (paper)." Isis 99, no. 4 (December 2008): 874–75. http://dx.doi.org/10.1086/597736.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

張琬琳, 張琬琳. "來自「東方」的聲音圖景：江文也作品的異國情調與民族追尋." 中正漢學研究 36, no. 36 (December 2020): 081–106. http://dx.doi.org/10.53106/2306036020201200360003.

Full text

Abstract:

<p>二十世紀初，在國際間崛起的各國勢力，加速了各民族內部自我整頓與反省的動力，東方音樂家學習西方音樂，也試圖以西方音樂的樂制，來整建自我民族內部的音樂紋理。</p> <p>東方音樂家欲望著西方，希冀能登上國際音樂舞臺；西方樂壇也期待從東方音樂家那裡，聽見西方人能夠「聽得懂」的「東方聲音」。在東 / 西方彼此期待、渴望之間，音樂本身被賦予極大的感官寓意，對西方人而言，帶有異國情調的音樂，尤其能夠吸引他們的目光；對於東方音樂家而言，這些「東方」的元素，卻是取自於不同民族風土的獨特聲音。</p> <p>本文聚焦臺灣近代音樂家江文也，以近年來新出版的傳記、日記和音樂作品全集，以及本論文作者近年於歐洲搜集的史料為分析佐證，探討江文也「屬於自己 / 東方的聲音」創作，如何引發西方樂壇對於「東方聲音」的想像。</p> <p> </p><p>The early twentieth century was a century that had the two global-scale World Wars between world powers across continents and oceans. Rising nationalism and increasing national awareness became a major political issue in general society. Eastern musicians reflected on the issue and diligently learned Western music system to get a remarkable grasp of it. Because they knew well the so-called Oriental music sounds must be rooted in the Western music theory to be able to compete among nations by international standards. On one hand, Eastern musicians desired to be seen and rival upon the world stage; on the other hand, Western musicians looked forward to hearing pure Oriental music sounds from the East. However, for Taiwanese composer Jiang, Wen-Ye, the Oriental music sounds are not the ones of a traditional and exotic concept. Traditionally, the Oriental music sounds derive its flavor from the pentatonic scale and use traditional Chinese musical instruments to play. It is under such circumstances Jiang, Wen-Ye compose beautiful musical forms that embody his love and respectful duty to the Taiwanese motherland throughout frequent international music events and competitions.</p> <p> </p>

APA, Harvard, Vancouver, ISO, and other styles

38

Wang, Zuoyue. "Jian Zhang. Ke xue she tuan zai jin dai Zhongguo de ming yun: yi Zhongguo ke xue she wei zhong xin [The Science Association and the Change of Society in Modern China: A Study on the Science Society of China]. (Zhongguo jin xian dai ke xue ji shu shi yan jiu cong shu.). 460 pp., tables, bibl., index. Jinan: Shandong jiao yu chu ban she [Shandong Education Press], 2005. ¥49 (paper)." Isis 99, no. 2 (June 2008): 437–38. http://dx.doi.org/10.1086/591376.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Xiang, Yuyao. "A Study of Spatial Aesthetics in the Film The Sun Also Rises." Studies in Art and Architecture 1, no. 1 (December 2022): 1–7. http://dx.doi.org/10.56397/saa.2022.12.01.

Full text

Abstract:

The Sun Also Rises was released in 2007, directed by Jiang Wen, Zhou Yun, Chen Chong and other powerful actors. The film is not only wonderful content, but also twists and turns of the plot. The story runs from the 1950s to the 1970s and tells the story of the love dispute between Li Bukong and his crazy mother and his wife, as well as the fate of various characters such as Nanyang overseas Chinese teacher Liang and Nurse Lin. Director Jiang Wen broke the fixed narrative mode of the film and split the story together again, so that the space and time of the film have a wonderful visual perception impact. This paper will the film The Sun Also Rises the space aesthetics as the research object, the space aesthetics presented in the film, based on the film depends on the spatial image construction and shooting skills, in order to analyze and study the space aesthetics and the film of the value and significance.

APA, Harvard, Vancouver, ISO, and other styles

40

Chenivesse, Sandrine, and Jiang Wen. "« Pour nous, Mao, c'est un premier grand amour ». Interview de Jiang Wen." Perspectives chinoises 25, no. 1 (1994): 53–57. http://dx.doi.org/10.3406/perch.1994.1786.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Wang, Guohui. "Principle-guided Policy Experimentation in China: From Rural Tax and Fee Reform to Hu and Wen's Abolition of Agricultural Tax." China Quarterly 237 (November 27, 2018): 38–57. http://dx.doi.org/10.1017/s0305741018001224.

Full text

Abstract:

AbstractThe abolition of Agricultural Tax in 2005 was a major policy of the early Hu–Wen administration. But how and why did it happen? Drawing on abundant media reports, archive documents and internal speeches by key policymakers, as well as on the author's interviews, this article argues that this reform was pushed through (the “how”) by “principle-guided policy experimentation” with origins in the period of Jiang Zemin's leadership. Not only does this show policy continuities from the Jiang–Zhu era into the Hu–Wen period, it also reveals a different process of policy experimentation from that identified by Sebastian Heilmann in the economic policy arena. Under principle-guided policy experimentation, Chinese central decision makers first reached consensus on the principle of the Rural Tax and Fee Reform (RTFR) drawing on policy learning from prior bottom-up local experimentation, and then formulated and implemented an experimental programme from the top-down, funding it in order to encourage local governments to participate. The evidence suggests that international, political (rural instability), economic and fiscal considerations came to explain leaders’ decisions (the “why”) on tax reform as much as their individual preferences.

APA, Harvard, Vancouver, ISO, and other styles

42

Sharifi, Hamid. "Intertextual relations in web localization." Journal of Internationalization and Localization 3, no. 2 (December 16, 2016): 152–64. http://dx.doi.org/10.1075/jial.3.2.03sha.

Full text

Abstract:

In this research, we studied localized commercial texts of globalized companies in the context of intertextuality on three levels: lexical, thematic, and cultural. Amongst many products of the three companies under study (Samsung, LG, and Sony), four smartphone models of each were selected (total: 12). Their introductory web pages both in Persian and English were the sources of the data. Furthermore, we used an online analyzer tool (online-utility.org/text/analyzer.jsp) so as to analyze the data; the results were also corroborated with other pieces of software packages and applications. In the scene of booming globalization, a better understanding of cross-cultural vocative communication proves to be helpful. One of the most active areas is to study flagship brands where rivals are trying their best at localizing their devices to the liking of potential customers. Descriptive and explanatory methods were brought into play in order to compare English and Persian commercial texts. The research revealed the critical role intertextuality plays in the process of glocalization. Developing companies should note that they, too, could utilize this great potentiality in the context of web localization. Therefore, the findings would be of benefit to Chief Executive Officers (CEOs), product developers and scholars interested in the subject.

APA, Harvard, Vancouver, ISO, and other styles

43

Albuquerque, Rui, Luís Cabral, and José Guedes. "Incentive Pay and Systemic Risk." Review of Financial Studies 32, no. 11 (March 4, 2019): 4304–42. http://dx.doi.org/10.1093/rfs/hhz028.

Full text

Abstract:

AbstractWe show that, in the presence of correlated investment opportunities across firms, risk sharing between firm shareholders and firm managers leads to compensation contracts that include relative performance evaluation. These contracts bias investment choices toward correlated investment opportunities, and thus create systemic risk. Furthermore, we show that leverage amplifies all such effects. In the context of the banking industry, we analyze recent policy recommendations for firm managerial pay and show how shareholders optimally undo the policies’ intended effects.Received October 31, 2017; editorial decision August 21, 2018 by Editor Wei Jiang. Authors have furnished an Internet Appendix, which is available on the Oxford University Press Web site next to the link to the final published paper online.

APA, Harvard, Vancouver, ISO, and other styles

44

Balasubramanian, N. "High-entropy alloys: An interview with Jien-Wei Yeh." MRS Bulletin 41, no. 11 (November 2016): 905–6. http://dx.doi.org/10.1557/mrs.2016.257.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Chenivesse, Sandrine. "La grande Révolution culturelle : un goût de fête [Des jours éblouissants de Jiang Wen]." Perspectives chinoises 25, no. 1 (1994): 51–53. http://dx.doi.org/10.3406/perch.1994.1785.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Mason, Peter G. "Fang-Ho Wan, Jian-Ying Guo, and Feng Zhang: Research on biological invasions in China." Biological Invasions 13, no. 2 (July 8, 2010): 527–29. http://dx.doi.org/10.1007/s10530-010-9832-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Shan, Chenxiao, Jia Li, Bo Sun, Runze Zhou, Min Xu, Qiulong Zhao, Ping Ren, Hongmei Wen, and Xi Huang. "Identification of absorbed compounds of Xiao Yao San Jia Wei and pharmacokinetic study in depressed rats by force swimming stress." RSC Advances 12, no. 8 (2022): 4455–68. http://dx.doi.org/10.1039/d1ra08778a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Liu, Fanxiao, Qingqi Meng, Heyong Yin, and Zexing Yan. "Stem Cells in Rotator Cuff Injuries and Reconstructions: A Systematic Review and Meta-Analysis." Current Stem Cell Research & Therapy 15, no. 7 (October 14, 2020): 646. http://dx.doi.org/10.2174/1574888x1507200810105414.

Full text

Abstract:

Current Stem Cell Research & Therapy, 2019, 14(8): 683-697 <P> Heyong Yin’s affiliation should be: Department of Orthopaedics, Beijing Friendship Hospital, Capital Medical University, Beijing China; <P> Zexing Yan’s affiliation should be: Department of Orthopaedics, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Road Jing Wu Wei Qi, Jinan 250021, Shandong, China. <P> The Original Paragraph Provided is Mentioned Below: <P> Fanxiao Liu1, Qingqi Meng2, Heyong Yin3,* and Zexing Yan3,* <P> 1Department of Orthopaedics, Shandong Provincial Hospital Affiliated to Shandong University, No.324, Road Jing Wu Wei Qi, Jinan 250021, Shandong, China; 3Department of Trauma Surgery, University of Regensburg, Am biopark 9, 93049 Regensburg, Germany

APA, Harvard, Vancouver, ISO, and other styles

49

Kim, Baik-Gyun. "Self-Consciousness of Wen (文) in Wei-Jin and North-South Dynasties and The Semantic Expansion of Xing (興) and Shen (神)." Journal of Aesthetics & Science of Art 67 (October 31, 2022): 60–81. http://dx.doi.org/10.17527/jasa.67.0.03.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Idwar, Idwar, and Enny Arita, Faradika. "E-Commerce Kue Bolu “Jihan” Kota Payakumbuh." Prosiding Konferensi Nasional Pengabdian Kepada Masyarakat dan Corporate Social Responsibility (PKM-CSR) 2 (December 15, 2019): 1383–91. http://dx.doi.org/10.37695/pkmcsr.v2i0.513.

Full text

Abstract:

E-commerce (Electronic Commerce) dapat juga didefinisikan sebagai aktivitas penggunaan teknologi informasi dan komunikasi pengolahan digital dalam melakukan transaksi bisnis untuk menciptakan, mengubah, dan mendefenisikan kembali hubungan antara penjual dan pembeli. E-commerce dapat diartikan sebagai aktivitas transaksi jual-beli barang, servis atau transmisi dana atau data dengan menggunakan elektronik yang terhubung dengan internet. Usaha ini Kue Bolu Jihan ini masih melakukan penjualan secara tradisional yaitu pada pasar tradisional yang mana penjual dan pembeli ketemu lansung. Jadi UKM ini mengalami kendala bagaimana cara penjualan secara elektronik. Untuk ini kami team pengabdian merumuskan permasalahan agar penjualan dapat berkembang maka dibuatlah sistem e-commerce. Tujuan dari pengabdian ini mendesign/memcreate sebuah teknologi/aplikasi e-commerce kue bolu JIHAN. Metode yang dikembangkan dengan konsep transaksi di dalam e-commerce ini, antara lain bisnis ke bisnis, bisnis ke konsumen, konsumen ke konsumen atau konsumen ke bisnis. Hasil yang hendak dicapai adalah desain web e-commerce pada konsep transaksi on line. Luaran yang hendak dicapai Web e-commerce, paten merek, dan publikasi ilmiah.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!